Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer.
Genes (Basel)
; 12(1)2020 12 29.
Article
de En
| MEDLINE
| ID: mdl-33383713
ABSTRACT
Pancreatic cancer is one of the most aggressive malignancies with limited treatment options thus resulting in high morbidity and mortality. Among all cancers, with a five-year survival rates of only 2-9%, pancreatic cancer holds the worst prognostic outcome for patients. To improve the overall survival, an earlier diagnosis and stratification of cancer patients for personalized treatment options are urgent needs. A minority of pancreatic cancers belong to the spectrum of Lynch syndrome-associated cancers and are characterized by microsatellite instability (MSI). MSI is a consequence of defective mismatch repair protein functions and it has been well characterized in other gastrointestinal tumors such as colorectal and gastric cancer. In the latter, high levels of MSI are linked to a better prognosis and to an increased benefit to immune-based therapies. Therefore, the same therapies could offer an opportunity of treatment for pancreatic cancer patients with MSI. In this review, we summarize the current knowledge about immune-based therapies and MSI in pancreatic cancer.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs du pancréas
/
Tumeurs colorectales héréditaires sans polypose
/
Instabilité des microsatellites
/
Immunothérapie
/
Récidive tumorale locale
Type d'étude:
Prognostic_studies
Limites:
Humans
Langue:
En
Journal:
Genes (Basel)
Année:
2020
Type de document:
Article
Pays d'affiliation:
Italie